Clinical Trial

Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 11, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 2, therapeutic exploratory study designed to evaluate the safety and efficacy of PG-102 compared with placebo. Part A includes Cohort A, comprising participants with type 2 diabetes mellitus (T2DM). Part B includes two cohorts: Cohort B1, enrolling participants with obesity, and Cohort B2, enrolling participants with both obesity and T2DM.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-26; most recent amendment 2025-07-08.
Status change: Recruiting → Active, Not Recruiting 2025-07-08
Status change: Enrolling by Invitation → Recruiting 2024-12-26
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-12-10
Trial Details
NCT Number NCT06712615
Lead Sponsor ProGen. Co., Ltd.
Conditions Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus
Enrollment 144 participants
Start Date 2024-12-05
Primary Completion 2025-10-30 (estimated)
Study Completion 2025-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-11